HUmira treatment in PSoriatic Arthritis (HUPSA) - a danish multicenter study of new imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in patients with psoriatic arthritis receiving Humira. - HUPSA

Hvidovre Hospital, Dept. of Rheumatology0 个研究点目标入组 40 人开始时间: 2006年2月21日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.Diagnosis of PsA according to Moll and Wright diagnostic criteria.
•2.Clinical active disease, defined as ³3 (of 76) swollen joints and ³ 3 (of 78) tender joints.
•3.Involvement of the hands (Clinical swelling of ³ 1 finger joint and/or ³1 sausage finger).
•4.Clinical indication for anti-TNFa therapy, according to treating physician.
•5.Adequate birth control.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Pregnant or breast-feeding women.
•2.No prior anti-TNFa-therapy.
•3.No treatment with other DMARDs than MTX later than 4 weeks before inclusion.
•4.No steroids later than 4 weeks before inclusion.
•5.No contraindikations for MRI.
•6.No other significant dermatological disorder tha psoriasis.
•7.No PUVA treatment or other UVA treatment later than 2 weeks before inclusion.
•8.No contraindications for anti-TNFa-therapy.

发起方

Hvidovre Hospital, Dept. of Rheumatology